AdipoGenix Inc., of Boston, appointed Nils Bergenhem chief scientific officer.
Alfacell Corp., of Bloomfield, N.J., appointed Jacob Maizel and Susanna Rybak to its scientific advisory board.
ArQule Inc., of Woburn, Mass., appointed Ronald Lindsay to its board.
Avera Pharmaceuticals Inc., of San Diego, appointed Joao Siffert vice president, clinical research and development.
Biopotential Capital Inc., of Calgary, Alberta, appointed Thomas Hudson to its scientific advisory board.
Ceragenix Pharmaceuticals, of Denver, appointed Russell Allen vice president of corporate development.
Ciphergen Biosystems Inc., of Fremont, Calif., appointed James Burns to its board.
Codexis Inc., of Redwood City, Calif., appointed William Haseltine special adviser to its board.
Coley Pharmaceutical Group Inc., of Wellesley, Mass., appointed Kenneth Bate, Robert Hugin and Patrick Langlois to its board.
CuraGen Corp., of New Haven, Conn., appointed Michael Astrue and Frank Armstrong to its board.
Cytomedix Inc., of Rockville, Md., appointed Andrew Maslan corporate controller.
Depomed Inc., of Menlo Park, Calif., appointed Carl Pelzel vice president, marketing and commercial development.
Emergent BioSolutions, of Gaithersburg, Md., appointed Jerome Hauer to its board.
Enzon Pharmaceuticals Inc., of Bridgewater, N.J., promoted Craig Tooman to executive vice president, finance, and chief financial officer.
Fox Chase Cancer Center, of Philadelphia, appointed James Greenwood to its board.
Gen-Probe, of San Diego, promoted Larry Mimms to executive vice president, research and development.
Helix BioPharma, of Aurora, Ontario, appointed Frank Michalargias chief financial officer.
Hybridon Inc., of Cambridge, Mass., appointed Robert Karr to its board.
i3 Research, of Basking Ridge, N.J., appointed Robert Shepard senior medical director of oncology, and Carl Kraus medical director of respiratory and infectious disease.
Immtech International Inc., of Vernon Hills, Ill., appointed Dolores Kapral director of clinical operations.
ImmuneRegen BioSciences, of Scottsdale, Ariz., appointed Moshe Arditi senior analyst to the bioterrorism preparedness advisory board.
ImmunoGen Inc., of Cambridge, Mass., appointed Nicole Onetto to its board.
ImpactRx Inc., of Mount Laurel, N.J., appointed Michael Hunt to its board, and Beth Everett chief information officer.
Isolagen Inc., of Exton, Pa., appointed Stephen Fanning to its board.
MacroPore Biosurgery Inc., of San Diego, appointed Alex Milstein vice president of clinical research, and Kenneth Chien scientific adviser.
Mesoblast Ltd., of Melbourne, Australia, appointed Tamara Lewis manager of clinical and regulatory affairs.
Millennium Pharmaceuticals Inc., of Cambridge, Mass., appointed Robert Friel to its board and a member of the audit committee.
MPM Capital LP, of Boston, promoted Ashley Dombkowski, Steven St. Peter and Ilan Zipkin to general partners.
New Life Scientific Inc., of Freehold, N.J., appointed Wieslaw Bochenek president and board member, and Eugene Zabolotsky corporate secretary and board member.
NicOx SA, of Sophia-Antipolis, France, appointed Ali Raza head of research and development.
Oxford Genome Sciences Ltd., of Oxford, UK, appointed Jeff Warren as its first nonexecutive director.
PDI Inc., of Saddle River, N.J., appointed Kevin Connolly executive vice president and general manager, medical education and communication.
Protein Polymer Technologies Inc., of San Diego, appointed William Plamondon and James McCarthy to its board.
pSivida Ltd., of Perth, Australia, appointed Jörg Schreiber nonexecutive director.